CAS: 3430-27-1; 3-Amino-4-Methylpyridine

相似化合物

180253-66-1 5832-44-0 78790-79-1

上下游产品

CAS号5832-44-0 4-甲基-3-硝基吡啶 | CAS号23056-39-5 2-氯-4-甲基-3-硝基吡啶 | CAS号129432-25-3 2,6-二氯-4-甲基-3-氨基吡啶 | CAS号7250-52-4 4-甲基烟酰胺 | CAS号21901-40-6 2-氨基-4-甲基-5-硝基吡啶 | CAS号6635-86-5 2-氨基-4-甲基-3-硝基吡啶 | CAS号7440-44-0 活性炭 | CAS号7440-05-3 钯 | CAS号76809-27-3 2,2-dimethyl-3-... | CAS号695-34-1 2-氨基-4-甲基吡啶 | CAS号393-53-3 3-氟吡啶-4-羧酸 | CAS号399-88-2 3-氟-4-甲基吡啶 | CAS号40273-47-0 3-氟吡啶-4-甲醛 | CAS号180253-66-1 (4-甲基吡啶-3-基)氨基甲酸叔丁酯 | CAS号2922-05-6 N-(4-甲基-吡啶-3-基)-苯甲酰胺 | CAS号2922-07-8 2-苯基-1H-吡咯并-2,3-c吡啶 | CAS号126325-50-6 2-溴-3-氨基-4-甲基吡啶 | CAS号126354-83-4 3-氨基-2,6-二溴-4-甲基吡啶 | CAS号133627-45-9 2-氯-3-氨基-4-甲基吡啶 | CAS号1121-19-3 3-羟基-4-甲基吡啶

3-硝基-4-甲基吡啶置于palladium On Activated Charcoal 氢气体系中,用 甲醇 用作溶剂,20.0 °C,500.0 Kpa 条件下,反应 5.0H,以97%的收率获得3-氨基-4-甲基吡啶
参考文献:制备4-取代的3-氨基-2-氯吡啶,合成奈韦拉平类似物
标题:制备4-取代的3-氨基-2-氯吡啶,合成奈韦拉平类似物
摘要:开发了一种新的制备3-氨基-2-氯吡啶的新方法,该3-氨基-2-氯吡啶在4-位具有取代基(甲基,苯基,羧酰胺,甲氧基羰基,乙酰基,苯甲酰基和氰基).逆转录酶抑制剂奈韦拉平的异喹啉类似物是由4-氨基-3-氯异喹啉合成的.
Doi:10.1002/jhet.5570380114

专利信息

专利号:US-7179919-B2
优先权日:2004-03-18
标 题 :Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
发明人：SONG JINHUA J; TAN ZHULIN; YEE NATHAN K; SENANAYAKE CHRIS HUGH; XU JINGHUA; GALLOU FABRICE
权利人:BOEHRINGER INGELHEIM PHARMA
摘要:A process for stereoselective synthesis of a compound of Formula (I) n nwherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein.

专利号:US-7425629-B2
优先权日:2005-09-30
标 题:Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
发明人：SONG JINHUA J; REEVES JONATHAN T; ROSCHANGAR FRANK; TAN ZHULIN; YEE NATHAN K
权利人:BOEHRINGER INGELHEIM PHARMA
摘要:A process for stereoselective synthesis of a compound of Formula (I) n nwherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein.

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:US-2005209488-A1
优先权日:2004-03-18
标 题 :Stereoselective synthesis of certain trifluoromethyl-substituted alcohols

专利号:US-2007100142-A1
优先权日:2005-09-30
标 题 :Stereoselective Synthesis of Certain Trifluoromethyl-Substituted Alcohols

专利号:US-6136982-A
优先权日:1999-01-22
标 题:Synthesis of 3-amino-2-chloro-4-methylpyridine from acetone and ethyl cyanoacetate
发明人：GROZINGER KARL
权利人:BOEHRINGER INGELHEIM PHARMA
摘要:A method for making 3-amino-2-chloro-4-methylpyridine from acetone and ethyl cyanoacetate, as depicted in the following reaction scheme. ##STR1##